Lisata Therapeutics, Inc. financial data

Symbol
LSTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
110 Allen Road, Second Floor, Basking Ridge, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Caladrius Biosciences, Inc. (to 9/15/2022), CALADRIUS BIOSCIENCES, INC. (to 9/15/2022), NeoStem, Inc. (to 6/5/2015), PHASE III MEDICAL INC/DE (to 9/1/2006), CORNICHE GROUP INC /DE (to 8/14/2003)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 860 % -28.9%
Debt-to-equity 13.3 % +41.5%
Return On Equity -51.2 % -41.6%
Return On Assets -45.2 % -36.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.39M shares +3.14%
Common Stock, Shares, Outstanding 8.32M shares +2.21%
Entity Public Float 25.1M USD -19.8%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 8.32M shares +2.21%
Weighted Average Number of Shares Outstanding, Diluted 8.32M shares +2.21%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 14.8M USD -3.58%
Operating Income (Loss) -23.5M USD +10.4%
Nonoperating Income (Expense) 1.95M USD -19.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.5M USD +9.49%
Income Tax Expense (Benefit) -1.6M USD -4.44%
Net Income (Loss) Attributable to Parent -20.7M USD +3.38%
Earnings Per Share, Basic -2.51 USD/shares -37.9%
Earnings Per Share, Diluted -2.51 USD/shares -37.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.5M USD -39.8%
Cash, Cash Equivalents, and Short-term Investments 30.3M USD -40.7%
Assets, Current 37.7M USD -34.1%
Property, Plant and Equipment, Net 96K USD -52.9%
Operating Lease, Right-of-Use Asset 182K USD -47.7%
Intangible Assets, Net (Excluding Goodwill) 400K USD 0%
Other Assets, Noncurrent 201K USD -45.8%
Assets 38.2M USD -34.2%
Accounts Payable, Current 556K USD -57.6%
Employee-related Liabilities, Current 2.13M USD -10%
Accrued Liabilities, Current 4.14M USD +8.25%
Liabilities, Current 4.69M USD -8.59%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 72K USD -71.5%
Liabilities 4.76M USD -11.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -32K USD +68%
Retained Earnings (Accumulated Deficit) -543M USD -3.97%
Stockholders' Equity Attributable to Parent 33.7M USD -36.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 33.4M USD -36.6%
Liabilities and Equity 38.2M USD -34.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.03M USD +14.3%
Net Cash Provided by (Used in) Financing Activities -142K USD -67.1%
Net Cash Provided by (Used in) Investing Activities 6.44M USD +50.1%
Common Stock, Shares Authorized 500M shares +1400%
Common Stock, Shares, Issued 8.32M shares +2.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -788K USD +80.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.5M USD -39.8%
Deferred Tax Assets, Valuation Allowance 23.5M USD +3.48%
Deferred Tax Assets, Gross 23.6M USD +2.79%
Operating Lease, Liability 181K USD -47.5%
Depreciation 29K USD -3.33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.7M USD +3.74%
Lessee, Operating Lease, Liability, to be Paid 191K USD -49.9%
Property, Plant and Equipment, Gross 661K USD 0%
Operating Lease, Liability, Current 181K USD +10.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 143K USD -24.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 143K USD -24.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10K USD -72.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 143K USD -24.7%
Deferred Tax Assets, Operating Loss Carryforwards 12.7M USD -3.02%
Preferred Stock, Shares Issued 10K shares 0%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 344K USD 0%
Additional Paid in Capital 578M USD +0.24%
Preferred Stock, Shares Outstanding 10K shares 0%
Amortization of Intangible Assets 20K USD -72.2%
Share-based Payment Arrangement, Expense 1.49M USD -26.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%